Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06312189 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Name: Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada — clinical trial record (NCT06312189)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusEnrolling by Invitation

PhasePhase 3

SponsorNeurocrine Biosciences

Started2024-04-24

View on ClinicalTrials.gov ↗

Amendment history

2026-06-16

Study Status, Outcome Measures v3

Primary completion pushed: 2026-04 → 2028-04

Completion pushed: 2026-04 → 2028-04

2026-04-06

Study Status v2

Re-verified, no change to tracked fields

2024-05-14

Study Status v1

Primary completion date2026-03→2026-04

Completion date2026-03→2026-04

Start dateestimated 2024-03→confirmed 2024-04-24

2024-03-08

Original filing

Neurocrine Biosciences

25 trials monitored

See 1 trial at risk

Huntington's Disease

78 trials monitored

See 3 trials at risk

This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.

Trial Details

NCT Number	NCT06312189
Lead Sponsor	Neurocrine Biosciences
Conditions	Chorea, Huntington
Enrollment	7 participants
Start Date	2024-04-24
Primary Completion	2028-04 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-18